Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

4D pharma press release feed
Clinical
4D pharma announces topline results from Blautix® Phase II trial in irritable bowel syndrome (IBS)
7 Oct 2020, 07:00
4D pharma announces topline results from Blautix® Phase II BHT-II-002 trial in IBS-C and IBS-D
Careers
Directorate Change
23 Sep 2020, 07:00
4D pharma makes strategic appointment of independent Non-Executive Director in response to new…
4D hosts R&D webinar discussing the world-leading MicroRx® LBP discovery platform
1 Sep 2020, 10:00
4D pharma's Research Director, Dr Imke Mulder, and members of her Research team provide an overview…
Clinical Update - comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®
26 Aug 2020, 07:30
4D pharma announces complete 6-month clinical benefit data from Part A of its ongoing trial of Live…
Clinical Update - 4D pharma treats first cancer patients in Part B of Phase I/II trial of MRx0518 in combination with Keytruda®
6 Jul 2020, 07:00
4D commences treatment of the first patients in Part B of its Phase I/II clinical trial of MRx0518…
Clinical Update - Phase II COVID-19 study open for enrolment
2 Jul 2020, 07:00
Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 open for enrolment. Dosing of…
4D hosts virtual R&D event providing updates on clinical programmes in oncology and COVID-19
5 Jun 2020, 07:45
4D's Chairman, CEO and CSO provide updates on the company’s clinical programmes in oncology and…
Clinical Update - Successful completion of immuno-oncology study safety phase
11 May 2020, 07:30
4D pharma plc announces successful completion of Part A of a Phase I/II clinical trial of MRx0518 in…
Clinical Update - Phase II COVID-19 study
20 Apr 2020, 07:00
4D announces expedited UK regulatory acceptance to commence Phase II study in COVID-19
Clinical Update - Interim analysis of Blautix Phase II study data
17 Apr 2020, 08:00
4D pharma plc today announces the key findings of a planned interim analysis in its BHT-II-0002…
4D pharma appoints Non-Executive Chairperson
17 Apr 2020, 08:00
4D pharma today announces that Prof. Axel Glasmacher, MD, has been appointed as Non-Executive…
Clinical Update - additional interim clinical data from MRx0518 combination study
17 Mar 2020, 08:00
4D presents an update on the previously reported interim data from its ongoing Phase I/II study of…
Clinical Update - 4D announce new study of MRx0518 in pancreatic cancer
6 Jan 2020, 08:00
4D pharma announces opening of a study investigating MRx0518 in combination with radiotherapy in…
Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA®
6 Nov 2019, 08:00
4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live…

BACK TO TOP